The table below shows ALNYLAM PHARMACEUTICALS, INC.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
Line item
Q1 2024
Q1 2023
Q1 2022
Q1 2021
Q1 2020
Q1 2019
Operating cash flow
-$81.52M
-$166.47M
-$171.19M
-$235.66M
-$246.16M
-$188.51M
Capital expenditure
$12.97M
$13.89M
$17.86M
$17.18M
$19.62M
$44.05M
Investing cash flow
-$67.62M
-$76.22M
-$147.42M
$71.35M
$113.69M
$102.65M
Dividends paid
-
-
-
ALNY operating cash flow (10-K history)
ALNYLAM PHARMACEUTICALS, INC. reported operating cash flow of $524.08M for fiscal year 2025. That is up 6405.1% from -$8.31M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow grew from -$307.70M (FY 2016) to $524.08M. Figures come from the company's audited annual reports as filed with the SEC.
